Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dolphin Medical ServicesBOM:526504 36 Return-on-Tangible-Equity is 0.45% as of Mar. 2026. GuruFocus rates BOM:526504 with a GF Score™ of 36/100 and a GF Value™ of ₹2.39 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Dolphin Medical Services ranks better than 54.17% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Dolphin Medical Services's annualized net income for the quarter that ended in Mar. 2026 was ₹0.28 Mil. Dolphin Medical Services's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹62.97 Mil. Therefore, Dolphin Medical Services's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 0.45%.
The historical rank and industry rank for Dolphin Medical Services's Return-on-Tangible-Equity or its related term are showing as below:
BOM:526504'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -12.71 Med: -2.94 Max: 0.97
Current: 0.97
During the past 13 years, Dolphin Medical Services's highest Return-on-Tangible-Equity was 0.97%. The lowest was -12.71%. And the median was -2.94%.
BOM:526504's Return-on-Tangible-Equity is ranked better than 54.17% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.605
vs BOM:526504: 0.97
Dolphin Medical Services (BOM:526504) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Dolphin Medical Services Return-on-Tangible-Equity Related Terms
Dolphin Medical Services Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Dolphin Medical Services's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dolphin Medical Services Return-on-Tangible-Equity Chart
BOM:526504 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Dolphin Medical Services's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dolphin Medical Services Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dolphin Medical Services's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Dolphin Medical Services's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.45% mean?
Dolphin Medical Services (BOM:526504) has a Return-on-Tangible-Equity of 0.45% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Dolphin Medical Services and its competitors. According to the industry distribution chart, Dolphin Medical Services ranks #88 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 45.8%.
Is Dolphin Medical Services' Return-on-Tangible-Equity too high?
Dolphin Medical Services' current Return-on-Tangible-Equity is 0.45%. Based on the distribution chart, Dolphin Medical Services ranks #88 out of 192 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Dolphin Medical Services has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dolphin Medical Services ranks #88 out of 192 companies for Return-on-Tangible-Equity. This puts Dolphin Medical Services in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Dolphin Medical Services and its competitors. Dolphin Medical Services's current Return-on-Tangible-Equity is 0.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.39, compared to a current price of ₹8.24 — trading 244.8% above its estimated fair value. The current Return-on-Tangible-Equity is 0.45%. Dolphin Medical Services' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current Return-on-Tangible-Equity is 0.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?
Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued.
The current stock price of ₹8.24 is trading 244.8% above its estimated GF Value™ of ₹2.39.
GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.
Key valuation signals for BOM:526504:
Return-on-Tangible-Equity: 0.45%
GF Value™: ₹2.39 vs. price of ₹8.24 (244.8% above fair value)
No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
36GF Score
Get the complete analysis for BOM:526504
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526504 has been successfully added to your 
